ORSERDU Drug Patent Profile

When do Orserdu patents expire, and what generic alternatives are available?

Orserdu is a drug marketed by Stemline Therap and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and sixty-nine patent family members in thirty countries.

The generic ingredient in ORSERDU is elacestrant hydrochloride. One supplier is listed for this compound. Additional details are available on the elacestrant hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Orserdu

Orserdu will be eligible for patent challenges on January 27, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2038. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ORSERDU

International Patents:	169
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	1
Patent Applications:	422
Drug Prices:	Drug price information for ORSERDU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORSERDU
What excipients (inactive ingredients) are in ORSERDU?	ORSERDU excipients list
DailyMed Link:	ORSERDU at DailyMed

See drug prices for ORSERDU

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ORSERDU

NDA:

217639

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ORSERDU

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Berlin-Chemie AG Menarini Group	Phase 1/Phase 2
Carrick Therapeutics Limited	Phase 1/Phase 2

See all ORSERDU clinical trials

Pharmacology for ORSERDU

Drug Class	Estrogen Receptor Antagonist
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Estrogen Receptor Antagonists P-Glycoprotein Inhibitors

US Patents and Regulatory Information for ORSERDU

ORSERDU is protected by seven US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No			Y	Y
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes

Expired US Patents for ORSERDU

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023
Stemline Therap	ORSERDU	elacestrant hydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023

International Patents for ORSERDU

When does loss-of-exclusivity occur for ORSERDU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORSERDU around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2943611
Cyprus	1125821
Cyprus	2024004
Denmark	3122426
Denmark	3834824
European Patent Office	3122426

Supplementary Protection Certificates for ORSERDU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3122426	CA 2024 00007	Denmark		PRODUCT NAME: ELACESTRANT OR A SALT THEREOF; REG. NO/DATE: EU/1/23/1757 20230918
3122426	2024C/505	Belgium		PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918
3122426	301263	Netherlands		PRODUCT NAME: ELACESTRANT, DESGEWENST IN DE VORM VAN ELACESTRANTDIHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/23/1757 20230918
3122426	LUC00331	Luxembourg		PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918
3122426	PA2024504	Lithuania		PRODUCT NAME: ELACESTRANTAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1757 20230915
3122426	122024000013	Germany		PRODUCT NAME: ELACESTRANT ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1757 20230915

ORSERDU (elacestrant) market dynamics and financial trajectory: launches, uptake drivers, payer posture, and IP/competitive risk

Last updated: July 30, 2026

ORSERDU (elacestrant) is priced and marketed as an oral estrogen receptor (ER)–targeted therapy in advanced/metastatic ER-positive breast cancer, with commercial demand tied to (1) the strength of clinical positioning versus endocrine alternatives, (2) biomarker-driven eligibility (ESR1 mutations and prior endocrine exposure), and (3) competitive pressure from ER degraders and CDK4/6 inhibitor sequencing. Its financial trajectory has followed a typical high-growth pattern for an oncology oral, then moderated as payers tightened coverage around molecular testing and as competitors expanded label breadth and access.

What is ORSERDU’s commercialization model and how has it performed financially?

Featured snippet: ORSERDU’s revenue path is driven by patient selection for ESR1-mutant disease, formulary access, and the integration of ER testing into clinical workflows for advanced/metastatic ER+/HER2− breast cancer after progression on prior endocrine therapy.

Where ORSERDU fits in therapy sequencing

ORSERDU is positioned for ER+/HER2− advanced or metastatic breast cancer in the setting of prior endocrine therapy, with label eligibility that depends on prior treatment history and biomarker status (notably ESR1 alterations). Commercially, this translates into:

• A demand pool that is smaller than broad “all comers” endocrine lines because testing and prior exposure are gating factors.
• Higher near-term value in oncology centers that rapidly adopt molecular testing.
• Slower expansion where ESR1 testing turnaround or payer coverage for the companion diagnostics is restrictive.

Financial trajectory shape: growth then plateau risk

Oral oncology launches in the US typically show:

• Early uptake led by high-volume academic/community networks adopting trial data.
• Subsequent deceleration when payer policies require prior authorization and proof of ESR1 status.
• Replacement pressure as competing targeted agents (including next-generation ER degraders) gain access and clinician comfort.

ORSERDU’s trajectory is consistent with this pattern: the key variable is how quickly it becomes the default ER-based option in the ESR1-positive, endocrine-pretreated subpopulation, and whether payers treat it as a preferred step therapy or a post-endocrine “option” rather than a line-therapy cornerstone.

What market dynamics drive ORSERDU uptake in ER+/HER2− breast cancer?

Featured snippet: ORSERDU uptake depends on biomarker prevalence, testing and payer coverage, clinician sequencing habits, and competition from other oral targeted therapies in endocrine-treated settings.

Biomarker and testing dynamics (ESR1)

The addressable market for ORSERDU in practice is constrained by ESR1 mutation frequency in real-world ER+/HER2− disease and by:

• Test availability (local lab vs centralized),
• Reimbursement for molecular profiling,
• Turnaround time that affects treatment selection.

If payers require ESR1 documentation before coverage approval, ORSERDU demand becomes sensitive to molecular testing adoption and sample logistics.

Payer posture and formulary access

In oncology, formulary access affects net price more than list price. Key dynamics include:

• Prior authorization and utilization management tied to label and testing,
• Step-therapy policies requiring prior endocrine regimens first,
• Contracting behavior at large PBMs and integrated delivery systems.

ORSERDU’s commercial performance is therefore tied to whether it becomes a “preferred oral endocrine/ER degrader” on formulary, or remains restricted to second-line or later use after multiple authorization steps.

Site-of-care dynamics

ORSERDU is an oral therapy. That typically shifts cost and access dynamics toward:

• Specialty pharmacy fulfillment,
• Patient co-pay burden and manufacturer assistance programs,
• Medical affairs influence on formulary committees and key accounts.

Orals generally penetrate faster than infusional therapies in systems that already manage specialty oral oncology drugs efficiently, but penetration slows where patient adherence support and copay infrastructure are weaker.

How does ORSERDU’s competitive landscape affect its revenue run-rate?

Featured snippet: Revenue growth for ORSERDU faces structural competition from other endocrine-targeted agents, ER degraders, and targeted regimens that can capture the same post-endocrine patient pool.

Direct competition categories

ORSERDU competes on clinical differentiation and practicality against:

• Other ER degraders and selective ER pathway agents,
• CDK4/6 inhibitor-based endocrine sequencing in eligible patients,
• Chemotherapy in later-line disease when endocrine options lose traction.

Even when ORSERDU’s label is narrower, clinicians may choose a different option due to:

• Prior exposure patterns,
• Biomarker-informed treatment protocols,
• Availability of a preferred oral on the formulary.

Competitive mechanism: “treatment sequencing” not just “head-to-head”

Commercial outcomes in advanced ER+ disease are determined by sequencing rules set by:

• Clinical guidelines and expert consensus,
• Institutional pathways,
• Evidence interpreted through real-world patient characteristics.

If competitor agents become preferred earlier in endocrine sequencing, ORSERDU’s later-line addressable pool shrinks even if its efficacy remains strong.

What are the key regulatory and label drivers that impact ORSERDU demand?

Featured snippet: ORSERDU’s sales trajectory is tied to label scope (indications, line of therapy, and biomarker rules), plus how FDA-approved guidance shapes clinician prescribing and payer coverage.

FDA approval framing and practical access

For oncology oral drugs, label language is often the boundary that:

• Determines payer eligibility criteria,
• Controls prior authorization checklists,
• Drives real-world uptake in line with coding and chart documentation.

When label eligibility maps cleanly onto routine biomarker testing and typical treatment histories, adoption accelerates. When it demands documentation that is slow or inconsistently collected, uptake lags.

How does ORSERDU pricing and net pricing dynamics affect its financial trajectory?

Featured snippet: For ORSERDU, net revenue performance depends on discounting, payer rebates, and patient access programs rather than headline list price alone.

Net price sensitivity

Oncology drugs face:

• Contract rebates tied to volume tiers and formulary placement,
• PBM performance-based contracts,
• Manufacturer assistance that can increase treatment starts while affecting “effective” net revenue through reimbursement mechanisms.

As competition increases, net pricing often compresses, shifting the revenue model from “price-led growth” to “volume-led growth.” If ORSERDU cannot maintain formulary status, volume growth can be offset by margin compression.

What patent and exclusivity factors determine ORSERDU’s medium-term revenue ceiling?

Featured snippet: ORSERDU’s revenue durability depends on the remaining life of composition, formulation, and method-of-use patents plus any granted exclusivities and litigation outcomes that affect generic or “authorized” competition timing.

Revenue risk channels for generics and market entrants

For small-molecule oncology orals, generic entry risk typically appears through:

• Paragraph IV ANDA challenges for oral solid dosage forms,
• Formulation workarounds if formulation patents exist and are enforceable,
• Launch delay if settlement agreements provide exclusivity windows.

A second risk channel is clinical substitution pressure: even without an immediate generic threat, competitors can erode market share and net pricing.

What generic entry risks exist for ORSERDU and when could they crystallize?

Featured snippet: Generic erosion timing for ORSERDU hinges on Orange Book patent expiry, FDA exclusivity (if any), and whether any ANDA Paragraph IV challenges produce market-launch triggers or settlement “carve-outs.”

Launch scenario logic used in forecasting

Medium-term revenue modeling generally uses:

• Earliest possible ANDA approval date based on Orange Book expiries,
• 180-day exclusivity for first-filer ANDA (if applicable),
• Patent-by-patent injunction or “carve-out” settlement outcomes,
• Practical payer switching behavior after generic availability.

If ORSERDU’s patent estate is thick and method-of-use claims remain enforceable, generic entry can be delayed or limited, reducing erosion speed.

How does ORSERDU compare with key ER-targeted competitors on market structure?

Featured snippet: ORSERDU’s market position is defined by where it lands in ER+/HER2− treatment sequencing and the strength of access for ESR1-mutant, endocrine-pretreated patients.

Comparison dimensions that drive share

Forecasting share requires looking at:

• Label coverage breadth and biomarker gating,
• Payer restrictions and preferred status,
• Ease of integration into molecular testing workflows,
• Evidence strength perceived by oncology decision-makers,
• Oral adherence considerations and specialty pharmacy infrastructure.

ORSERDU tends to be evaluated as an ER pathway option for a defined subpopulation. That structure produces higher early differentiation but greater share vulnerability if competitors secure preferred status earlier in the line-of-therapy pathway.

What does the ORSERDU commercial outlook imply for financial trajectory under base, downside, and upside cases?

Featured snippet: ORSERDU’s financial trajectory is likely to remain growth-positive in the near term if ESR1 testing adoption and formulary status persist, then becomes sensitive to (1) payer tightening, (2) competitive label expansion, and (3) any step-down in net pricing.

Base case (continuing adoption within ESR1 gating)

• Volume grows with steady penetration in molecular-tested populations.
• Net price remains stable to modestly declining as contracts normalize.

Downside case (formulary restriction or slower testing adoption)

• Prior authorization and testing requirements constrain conversions from eligible to treated.
• Competitors capture the remaining endocrine-targeted share due to earlier sequencing placement or broader label.

Upside case (broader access and strong preferred positioning)

• ORSERDU becomes a formulary “preferred” oral in ESR1-mutant disease.
• Lower friction in patient starts drives volume growth faster than pricing compression.

Key Takeaways

• ORSERDU’s market dynamics are driven by biomarker-gated eligibility (ESR1), payer authorization mechanics, and sequencing behavior in ER+/HER2− advanced breast cancer.
• Its financial trajectory typically follows oncology oral patterns: early growth via differentiation and adoption, then moderation as payer restrictions and competitive substitutes expand.
• The medium-term revenue ceiling is shaped by net pricing durability and the enforceability of the remaining patent and exclusivity landscape.
• Generic entry timing risk must be modeled from Orange Book expiries, exclusivities, and litigation/settlement behavior, while clinical competition can erode share even without immediate generic threats.

FAQs

1. What patient segments drive the majority of ORSERDU prescriptions in routine practice?
2. How do prior authorization and ESR1 testing requirements affect ORSERDU treatment starts?
3. What contract levers most influence ORSERDU net revenue versus list price?
4. Which competitive ER-targeted therapies most threaten ORSERDU share through sequencing changes?
5. What forecasting framework best maps ORSERDU revenue to patent expiry, exclusivity, and formulary switching?

References

1. [No cited sources were included in the provided prompt content; therefore no references are listed.]

DrugChatter Q&A for ORSERDU

How does orserdu treat breast cancer?